• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

配体结合分析关键试剂及其稳定性:全球生物分析联盟协调小组的建议和最佳实践。

Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team.

机构信息

Pfizer, Inc., Building 220, MS 8220-2468, 600 Eastern Point Road, Groton, Connecticut, 06340, USA,

出版信息

AAPS J. 2014 May;16(3):504-15. doi: 10.1208/s12248-014-9583-x. Epub 2014 Apr 1.

DOI:10.1208/s12248-014-9583-x
PMID:24687208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4012044/
Abstract

The L4 Global Harmonization Team on reagents and their stability focused on the management of critical reagents for pharmacokinetic, immunogenicity, and biomarker ligand binding assays. Regulatory guidance recognizes that reagents are important for ligand binding assays but do not address numerous aspects of critical reagent life cycle management. Reagents can be obtained from external vendors or developed internally, but regardless of their source, there are numerous considerations for their reliable long-term use. The authors have identified current best practices and provided recommendations for critical reagent lot changes, stability management, and documentation.

摘要

L4 全球协调小组(Global Harmonization Team)关于试剂及其稳定性的重点是管理药代动力学、免疫原性和生物标志物配体结合测定法的关键试剂。监管指南认识到试剂对于配体结合测定法很重要,但并未涉及关键试剂生命周期管理的许多方面。试剂可以从外部供应商处获得,也可以内部开发,但无论其来源如何,在可靠的长期使用方面都有许多需要考虑的因素。作者已经确定了当前的最佳实践,并提供了关于关键试剂批变化、稳定性管理和文件记录的建议。

相似文献

1
Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team.配体结合分析关键试剂及其稳定性:全球生物分析联盟协调小组的建议和最佳实践。
AAPS J. 2014 May;16(3):504-15. doi: 10.1208/s12248-014-9583-x. Epub 2014 Apr 1.
2
Critical ligand binding reagent preparation/selection: when specificity depends on reagents.关键配体结合试剂的制备/选择:当特异性取决于试剂时。
AAPS J. 2007 May 11;9(2):E148-55. doi: 10.1208/aapsj0902016.
3
EBF recommendation on practical management of critical reagents for PK ligand-binding assays.欧洲生物制药联合会(EBF)关于PK配体结合分析关键试剂实际管理的建议。
Bioanalysis. 2018 Oct 1;10(19):1557-1565. doi: 10.4155/bio-2018-0230. Epub 2018 Sep 18.
4
Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.21 世纪实验室中的配体结合分析:关键试剂的特性描述和供应建议。
AAPS J. 2012 Jun;14(2):316-28. doi: 10.1208/s12248-012-9334-9. Epub 2012 Mar 14.
5
Critical reagent inventory management system and web portal specifically optimized for supporting external clients.关键试剂库存管理系统和网络门户,专门针对支持外部客户进行了优化。
Bioanalysis. 2022 Jun;14(12):869-879. doi: 10.4155/bio-2022-0096. Epub 2022 Jul 29.
6
Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents.治疗性蛋白质生物分析中关键分析试剂的质量要求:生物分析人员应了解的试剂知识。
Bioanalysis. 2011 Mar;3(5):523-34. doi: 10.4155/bio.11.16.
7
Adventures in critical reagent lot changes in ligand-binding assays: redevelopment, bridging and additional processing requirements.在配体结合分析中进行关键试剂批次变更的冒险经历:重新开发、桥接和额外的处理要求。
Bioanalysis. 2021 May;13(10):771-777. doi: 10.4155/bio-2020-0216. Epub 2021 Apr 22.
8
Quality Controls in Ligand Binding Assays: Recommendations and Best Practices for Preparation, Qualification, Maintenance of Lot to Lot Consistency, and Prevention of Assay Drift.配体结合分析的质量控制:关于准备、鉴定、批间一致性维护以及防止分析漂移的建议和最佳实践。
AAPS J. 2019 Jul 11;21(5):89. doi: 10.1208/s12248-019-0354-6.
9
Critical reagent generation, characterization, handling and storage workflows: impact on ligand binding assays.关键试剂的生成、特性描述、操作和储存流程:对配体结合分析的影响。
Bioanalysis. 2021 May;13(10):847-860. doi: 10.4155/bio-2020-0252. Epub 2021 Apr 23.
10
Stability: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team.稳定性:全球生物分析联盟协调小组的最佳实践和协调建议。
AAPS J. 2014 May;16(3):392-9. doi: 10.1208/s12248-014-9573-z. Epub 2014 Feb 19.

引用本文的文献

1
The case for calibration-free concentration analysis.无校准浓度分析的情况
Bioanalysis. 2025 Jun;17(11):759-765. doi: 10.1080/17576180.2025.2517530. Epub 2025 Jun 12.
2
2024 White paper on recent issues in bioanalysis: Impact of LDT in US and IVDR in EU; AI/ML for High Parameter Flow Cytometry; The rise of Olink Technology; CDx for AAV Gene Therapies; Integrative Bioanalysis by Multiple Platforms; Super Sensitive ADA/NAb LBA ( - Recommendations on Advanced Strategies for Biomarkers, IVD/CDx Assays (BAV), Cell Based Assays (CBA), and Ligand-Binding Assays (LBA) - Regulatory Agencies' Input on Biomarkers, IVD/CDx, and Biomarker Assay Validation).2024年生物分析近期问题白皮书:美国实验室开发检测(LDT)和欧盟体外诊断医疗器械法规(IVDR)的影响;用于高参数流式细胞术的人工智能/机器学习;欧林克技术的兴起;腺相关病毒(AAV)基因疗法的伴随诊断(CDx);多平台整合生物分析;超灵敏抗药物抗体/中和抗体配体结合分析(LBA)(-关于生物标志物、体外诊断/伴随诊断检测(BAV)、基于细胞的检测(CBA)和配体结合分析(LBA)的先进策略建议-监管机构对生物标志物、体外诊断/伴随诊断及生物标志物检测验证的意见)
Bioanalysis. 2025 Feb;17(4):211-248. doi: 10.1080/17576180.2024.2442218. Epub 2025 Jan 25.
3
A comprehensive LC-MS based study of factors influencing biotinylation of critical reagents.一项基于液相色谱-质谱联用技术的关于影响关键试剂生物素化因素的综合性研究。
Bioanalysis. 2024;16(16):895-904. doi: 10.1080/17576180.2024.2394317. Epub 2024 Sep 4.
4
Neutralizing Antibody Sample Testing and Report Harmonization.中和抗体样本检测及报告协调
AAPS J. 2024 Jul 12;26(4):80. doi: 10.1208/s12248-024-00955-1.
5
Immunocapture LC-MS methods for pharmacokinetics of large molecule drugs.免疫捕获 LC-MS 法用于测定大分子药物的药代动力学。
Bioanalysis. 2024 Apr;16(7):165-177. doi: 10.4155/bio-2023-0261. Epub 2024 Feb 13.
6
A Case Study for Critical Reagent Qualification for Ligand Binding Assays Using Equivalence Test Methodology.使用等效性测试方法对配体结合分析的关键试剂进行资格认证的案例研究。
AAPS J. 2023 Sep 15;25(5):89. doi: 10.1208/s12248-023-00857-8.
7
Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays.采用总抗体检测法评估基于腺相关病毒的基因治疗模式的体液免疫反应。
AAPS J. 2021 Sep 16;23(6):108. doi: 10.1208/s12248-021-00628-3.
8
Recommendations for Selection and Characterization of Protein Biomarker Assay Calibrator Material.用于选择和鉴定蛋白质生物标志物测定校准品材料的建议。
AAPS J. 2017 Nov;19(6):1550-1563. doi: 10.1208/s12248-017-0146-9. Epub 2017 Oct 2.
9
Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.药物研发中生物标志物多重配体结合分析的使用建议及适用性验证
AAPS J. 2016 Jan;18(1):1-14. doi: 10.1208/s12248-015-9820-y. Epub 2015 Sep 16.
10
Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics.蛋白质生物治疗药物液相色谱-串联质谱生物分析方法验证的建议。
AAPS J. 2015 Jan;17(1):1-16. doi: 10.1208/s12248-014-9685-5. Epub 2014 Nov 13.

本文引用的文献

1
The European Bioanalysis Forum community's evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method Validation.欧洲生物分析论坛团体对欧洲药品管理局生物分析方法验证指南的评估、解读及实施。
Bioanalysis. 2013 Mar;5(6):645-59. doi: 10.4155/bio.13.19.
2
Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management.配体结合分析中关键试剂的表征:建立可靠的生物分析方法及全生命周期管理
Bioanalysis. 2013 Jan;5(2):227-44. doi: 10.4155/bio.12.304.
3
Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix(®), a CTLA-4-Fc fusion protein, in renal and liver transplant patients.用于测定肾移植和肝移植患者体内CTLA-4-Fc融合蛋白Nulojix(®)的定量配体结合分析方法的验证及生命周期管理
Bioanalysis. 2012 Jun;4(10):1215-26. doi: 10.4155/bio.12.79.
4
Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.21 世纪实验室中的配体结合分析:关键试剂的特性描述和供应建议。
AAPS J. 2012 Jun;14(2):316-28. doi: 10.1208/s12248-012-9334-9. Epub 2012 Mar 14.
5
Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents.治疗性蛋白质生物分析中关键分析试剂的质量要求:生物分析人员应了解的试剂知识。
Bioanalysis. 2011 Mar;3(5):523-34. doi: 10.4155/bio.11.16.
6
Commutability limitations influence quality control results with different reagent lots.可比性限制会影响不同试剂批次的质量控制结果。
Clin Chem. 2011 Jan;57(1):76-83. doi: 10.1373/clinchem.2010.148106. Epub 2010 Nov 19.
7
Role of protein stabilizers on the conformation of the unfolded state of cytochrome c and its early folding kinetics: investigation at single molecular resolution.蛋白质稳定剂对细胞色素 c 展开态构象及其早期折叠动力学的作用:单分子水平的研究。
J Biol Chem. 2010 Aug 13;285(33):25314-23. doi: 10.1074/jbc.M110.116673. Epub 2010 Jun 10.
8
Goals of stability evaluation throughout the vaccine life cycle.疫苗整个生命周期稳定性评估的目标。
Biologicals. 2009 Nov;37(6):369-78; discussion 421-3. doi: 10.1016/j.biologicals.2009.08.015. Epub 2009 Sep 22.
9
Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories.良好临床实验室规范指南:弥合研究实验室与临床研究实验室之间的运营差距
J Pharm Biomed Anal. 2008 Jan 7;46(1):18-29. doi: 10.1016/j.jpba.2007.10.010. Epub 2007 Oct 13.
10
Antimicrobial preservative use in parenteral products: past and present.注射用产品中抗菌防腐剂的使用:过去与现在。
J Pharm Sci. 2007 Dec;96(12):3155-67. doi: 10.1002/jps.20976.